Dasatinib (anhydrous) is an aminopyrimidine with a 2-methylpyrimidine core. Position 4 is substituted by a primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid, and position 6 is substituted by a 4-(2-hydroxyethyl)piperazin-1-yl group. The carboxylic acid group is condensed with 2-chloro-6-methylaniline to form an amide. It is a multi-targeted kinase inhibitor used primarily as the monohydrate for treating chronic, accelerated, or myeloid/lymphoid blast phase chronic myeloid leukemia. The name 'dasatinib' refers to both the monohydrate (USAN) and anhydrous form (INN). It functions as a tyrosine kinase inhibitor, anticoronaviral agent, and antineoplastic agent. It is a secondary and tertiary amino compound, an organochlorine compound, an aminopyrimidine, a member of 1,3-thiazoles, a monocarboxylic acid amide, an N-arylpiperazine, and an N-(2-hydroxyethyl)piperazine. It is also the conjugate base of dasatinib(1+).
